Brief: MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MetaVia

22/04/2025 13:33

April 22 (Reuters) - MetaVia Inc MTVA.O:

METAVIA REPORTS ADDITIONAL POSITIVE TOP-LINE RESULTS FROM THE MAD PART 2 OF ITS PHASE 1 STUDY OF DA-1726, A NOVEL 3:1 RATIO GLP-1 AND GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, FURTHER DEMONSTRATING ITS BEST-IN-CLASS POTENTIAL

METAVIA INC: A DOSE-DEPENDENT RESPONSE IN BODY WEIGHT REDUCTION WAS OBSERVED BETWEEN 8 MG AND 32 MG DOSES

METAVIA INC: CHANGE IN BMI AND BODY WEIGHT ADJUSTED FOR HEIGHT IN TREATMENT GROUPS, SHOWED A SIGNIFICANT DIFFERENCE COMPARED TO PLACEBO

METAVIA: NO DRUG-INDUCED CARDIOVASCULAR EFFECTS OBSERVED IN HEART RATE/QTCF MEASUREMENTS OF SUBJECTS GETTING UP TO 32 MG OF DA-1726 AT 4-WEEKS

METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE

Source text: ID:nPn48yhCwa

Further company coverage: MTVA.O

 ((Reuters.Briefs@thomsonreuters.com;))